Current stage -Stage II - Page 2 of 4 Posts on Medivizor
Navigation Menu

Current stage -Stage II Posts on Medivizor

Searching for men with intermediate- or high-risk prostate cancer to test a short course of very focused radiation therapy

Posted by on Feb 6, 2017 in Prostate cancer | 0 comments

In a nutshell This phase 2 trial aims to compare conventional radiation therapy with a very focused type of radiation therapy for intermediate- and high-risk prostate cancer. The main outcome to be investigated is the number of side effects and the rate of disease recurrence at 5 years. The trial is recruiting in British Columbia, Canada. The details...

Read More

Survival benefits for men treated with local therapies before starting chemotherapy

Posted by on Nov 21, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined the benefits of administering local therapies before chemotherapy for prostate cancer. Researchers reported lower mortality risks for men treated with local therapies before chemotherapy. Some background Local therapies, such as surgery or radiation, are first-line treatments for localized (confined) prostate...

Read More

The effect of combined radiation and hormone therapy on long-term fatigue

Posted by on Jul 18, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined the effect of combined radiation and hormone therapy on long-term fatigue. Researchers reported severe fatigue during and up to 4 years after treatment. Men with increased cancer markers and symptoms were more likely to report higher fatigue levels. Some background Radiation therapy and hormone therapy are often...

Read More

Lower PSA levels increase or decrease mortality risk depending on Gleason score

Posted by on May 21, 2016 in Prostate cancer | 0 comments

In a nutshell This study evaluated prostate-specific mortality risk based on PSA (prostate specific antigen) levels in men with high-grade disease. Authors reported increased mortality risk with lower PSA levels in men with high-grade disease. A decreased mortality risk was observed with lower PSA levels in men with low-grade disease. Some background...

Read More

Low-risk prostate cancer: Predictors of disease progression during active surveillance

Posted by on Apr 2, 2016 in Prostate cancer | 0 comments

In a nutshell This review examined predictors of disease progression in low-risk prostate cancer during active surveillance. Researchers concluded that certain blood markers, biopsy results, and ethnicity could help predict which patients were more likely to experience disease progression.  Some background Active surveillance of prostate...

Read More

LDH as an early predictor of cancer survival

Posted by on Feb 8, 2016 in Prostate cancer | 1 comment

In a nutshell This study investigated the relationship between lactate dehydrogenase (LDH) levels and cancer-specific survival. Researchers concluded that LDH can be used as an early indicator of cancer outcomes. Some background Early cancer detection methods have significantly improved cancer survival rates. There is increasing evidence to...

Read More

Identifying prostate cancer progression

Posted by on Apr 29, 2015 in Prostate cancer | 0 comments

In a nutshell The authors aimed to identify the best options available to identify metastatic prostate cancer. Some background Metastatic prostate cancer is cancer that has spread from the prostate gland into tissues and organs around the body. In some cases patients with metastatic cancer can become resistant to certain treatments, such as...

Read More

The complications associated with hormone therapy in advanced prostate cancer

Posted by on Apr 29, 2015 in Prostate cancer | 0 comments

In a nutshell The authors aimed to determine the complications of hormone therapy in patients with advanced prostate cancer.  Some background Hormone therapy is a prostate cancer treatment that targets the male sex hormones, such as testosterone, active in cancer. In some patients hormone therapy can cause side effects such as bone damage,...

Read More